FDA Finds No Misconduct By Care Access In Pfizer's Lyme Vaccine Trial; Research Co Care Access Announces Completion Of For-Cause FDA Good Clinical Practices Inspection Related To Co's Activities On Pfizer Valor Trial
Portfolio Pulse from Benzinga Newsdesk
The FDA has found no misconduct by Care Access in Pfizer's Lyme vaccine trial. The research company Care Access has announced the completion of a for-cause FDA Good Clinical Practices inspection related to the company's activities on Pfizer's Valor trial.
October 11, 2023 | 3:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's Lyme vaccine trial conducted by Care Access has been cleared of any misconduct by the FDA. This could potentially boost investor confidence in Pfizer.
The FDA's clearance of any misconduct in Pfizer's Lyme vaccine trial conducted by Care Access is a positive development for Pfizer. This could potentially boost investor confidence in the company and its ongoing trials, leading to a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100